07/01/2024 10:00 |
Corporate Governance Report |
05/14/2024 13:00 |
Sumitomo Pharma Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Director and Executive Officer. |
05/14/2024 13:00 |
Sumitomo Pharma Announces Reduction in Executive Remuneration |
05/14/2024 13:00 |
Conference on FY2023 (April 1,2023 to March 31, 2024) Financial Results |
05/14/2024 13:00 |
Summary of Consolidated Financial Results for the Year Ended March 31, 2024 [IFRS] |
05/14/2024 13:00 |
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2024 |
05/09/2024 19:30 |
Notice of Company Split of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company |
04/30/2024 08:45 |
Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 |
04/30/2024 08:30 |
Sumitomo Pharma Announces Its Financial Forecasts Revision for FY2023, Financial and Dividend Forecasts for FY2024 |
04/30/2024 08:30 |
Notice Concerning Impairment Losses, Business Structure Improvement Expenses, and Finance Income |
04/02/2024 20:00 |
Sumitomo Pharma Announces Sale of Strategic Shareholdings |
03/15/2024 15:30 |
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License for Four Compounds Including Ulotaront with Otsuka |
03/04/2024 22:00 |
Sumitomo Pharma Announces Reduction of Workforce and Other Rationalization Measures of the USA Consolidated Subsidiary |
01/31/2024 15:30 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts |
01/31/2024 15:30 |
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2024 [IFRS] |
01/31/2024 15:30 |
Conference on Q3 FY2023 (April 1 to December 31, 2023) Financial Results |
01/31/2024 15:30 |
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2024 |
01/31/2024 15:30 |
Notice Concerning Finance Income |
01/31/2024 15:30 |
Posting of Business Structure Improvement Expenses |
11/28/2023 09:35 |
Corporate Governance Report |
10/31/2023 13:30 |
Conference on Q2 FY2023 (April 1 to September 30, 2023) Financial Results |
10/31/2023 13:30 |
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2024 |
10/31/2023 13:30 |
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2024 [IFRS] |
10/31/2023 13:30 |
Notice Concerning Finance Income |
10/31/2023 13:30 |
Posting of Business Structure Improvement Expenses |
07/31/2023 15:30 |
Posting of Business Structure Improvement Expenses |
07/31/2023 15:30 |
Notice Concerning Finance Income |
07/31/2023 15:30 |
Conference on Q1 FY2023 (April 1 to June 30, 2023) Financial Results |
07/31/2023 15:30 |
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2024 |
07/31/2023 15:30 |
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2024 [IFRS] |
07/31/2023 08:30 |
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND1 and DIAMOND2 Clinical Studies Evaluating Ulotaront in Schizophrenia |